Pharma Mac Pac

pharmamacpac.com

Pharma Mac Pac Expo : International Exhibition & Conference on Pharma Machinery & Packaging. 21st - 23rd November 2013, Hitex Exhibition Centre, Hyderabad, India. Pharma Mac Pac Expo is important for :- Plant & Machinery for Pharmaceutical Production & Processing, Packaging Materials & Machinery, Pollution Control Products & Services, Safety Equipments & Services, Automation & Instrumentation, Automation & Robotics, Batching Equipment, Filling Equipment, Filtration & Separation, Water Purification & Management, Packaging Equipment & Supplies, Plant & Facility Equipment, Tablet & Capsule Fillers

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

news image

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

news image

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More

Business Insights, PHARMA TECH

ENDO LAUNCHES BIVALIRUDIN INJECTION IN READY-TO-USE VIALS

PRNewswire | July 19, 2023

news image

Endo International plc announced that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S. "Hospital practitioners work hard to provide quality patient care while also meeting operational challenges," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "With rea...

Read More

Pharmacy Market

CARDURION PHARMACEUTICALS ANNOUNCES INVESTMENT OF UP TO $300 MILLION FROM BAIN CAPITAL

Cardurion Pharmaceuticals | October 28, 2021

news image

Cardurion Pharmaceuticals, Inc a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors, Takeda Pharmaceuticals and Polaris Partners, in supporting the evolution of Cardurion into a leading ...

Read More
news image

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More
news image

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More
news image

Business Insights, PHARMA TECH

ENDO LAUNCHES BIVALIRUDIN INJECTION IN READY-TO-USE VIALS

PRNewswire | July 19, 2023

Endo International plc announced that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S. "Hospital practitioners work hard to provide quality patient care while also meeting operational challenges," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "With rea...

Read More
news image

Pharmacy Market

CARDURION PHARMACEUTICALS ANNOUNCES INVESTMENT OF UP TO $300 MILLION FROM BAIN CAPITAL

Cardurion Pharmaceuticals | October 28, 2021

Cardurion Pharmaceuticals, Inc a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors, Takeda Pharmaceuticals and Polaris Partners, in supporting the evolution of Cardurion into a leading ...

Read More